Allelic Imbalance Analysis of Imprinted Growth-Regulatory Genes in Fetal Development

Abstract

Allelic imbalance analysis examines whether the two parental alleles of a gene are expressed at unequal levels. In fetal development, this approach is particularly important for imprinted growth-regulatory genes, which are epigenetically marked according to parental origin and expressed preferentially from either the maternal or paternal allele. Imprinted loci coordinate placental function, nutrient allocation, cellular proliferation, differentiation, and postnatal metabolic adaptation. Abnormal allelic dosage, loss of imprinting, uniparental disomy, copy-number variation, and methylation defects can therefore produce major developmental consequences, including fetal growth restriction, overgrowth, placental dysfunction, neurodevelopmental abnormalities, and susceptibility to later cardiometabolic disease. Modern analysis combines methylation-sensitive assays, allele-specific RNA sequencing, quantitative PCR, chromatin profiling, and genomic phasing. Clinically, results must be interpreted alongside gestational age, parental genotype, placental pathology, ultrasound findings, and family history. This review summarizes the biological basis, clinical relevance, diagnostic workflow, management implications, and emerging therapeutic directions for allelic imbalance analysis in fetal growth regulation.

Introduction

Genomic imprinting is a parent-of-origin-dependent epigenetic process in which a subset of genes is expressed predominantly from one parental allele. Unlike conventional biallelic expression, imprinting creates functional haploidy at selected loci, making the active allele especially vulnerable to pathogenic variants, epigenetic disruption, or abnormal chromosomal inheritance. Imprinted growth-regulatory genes are concentrated in genomic domains that influence fetal growth, placental development, endocrine signaling, and energy balance. Important examples include regions containing IGF2 and H19, CDKN1C, PLAGL1, DLK1, PEG3, and related regulatory elements.

Allelic imbalance refers to a measurable departure from the expected expression ratio between maternal and paternal alleles. It may reflect altered imprinting, somatic mosaicism, a cis-regulatory variant, copy-number change, uniparental disomy, or a broader chromatin abnormality. In fetal medicine and molecular pathology, this analysis can clarify cases in which ultrasound identifies abnormal growth but routine karyotyping or noninvasive screening is unrevealing. The interpretation is technically complex because imprinting may be tissue-specific, developmental-stage-dependent, and different between placenta and fetal organs. Accordingly, laboratory results should be integrated with clinical and genomic data rather than treated as isolated diagnostic findings.

Epidemiology / Disease Burden

Abnormal fetal growth is common in obstetric practice, although only a proportion of cases are attributable to imprinting disorders. Fetal growth restriction is associated with placental insufficiency, maternal disease, infection, chromosomal abnormalities, fetal malformations, and genetic syndromes. Conversely, fetal overgrowth may result from diabetes, constitutional factors, fetal overgrowth syndromes, or altered dosage of growth-promoting genes. Imprinting-related conditions are individually uncommon but collectively important because they can affect multiple organ systems and may recur in families when a pathogenic variant or an inherited imprinting-center defect is present.

The disease burden extends beyond birth size. Children with imprinting disturbances may develop feeding problems, hypoglycemia, developmental delay, endocrine abnormalities, renal or genitourinary findings, obesity, insulin resistance, or tumor predisposition, depending on the affected locus. Placental imprinting defects can also influence nutrient transport and vascular development, creating a mechanistic link between abnormal fetal growth and later-life cardiovascular or metabolic risk. Improved molecular recognition is therefore relevant to prenatal counseling, neonatal surveillance, and long-term preventive care.

Pathophysiology

Imprinted domains are regulated by differentially methylated regions, allele-specific histone modifications, chromatin looping, noncoding RNAs, and insulator elements. These mechanisms establish parental identity in the germline and maintain it after fertilization through successive rounds of cell division. At the IGF2-H19 domain, for example, parent-specific methylation controls enhancer access and influences the balance between growth-promoting and growth-restraining transcripts. At the 11p15 region, disruption of methylation or chromosomal dosage can alter fetal growth, placental biology, and postnatal endocrine function.

Allelic imbalance can arise through several mechanisms. A sequence variant may increase or reduce transcription from the active allele. Loss of methylation may silence an allele that should be expressed, while gain of methylation may activate an inappropriate parental copy. Uniparental disomy can result in two copies of one parental chromosome segment and no copy of the other, effectively changing the dosage of multiple imprinted genes. Mosaic abnormalities may be confined to the placenta, leading to discordance between placental testing and fetal tissues. These biological mechanisms explain why a single blood sample may not fully represent the molecular state of the developing fetus.

Risk Factors

Risk factors include a previous pregnancy affected by a confirmed imprinting disorder, a known familial pathogenic variant, assisted reproductive technology, abnormal parental chromosomal rearrangement, and a history of recurrent unexplained fetal growth abnormalities. Advanced parental age and consanguinity may increase the likelihood of certain genetic conditions, although they are not specific predictors of imprinting defects. Abnormal first-trimester growth, disproportionate fetal measurements, placentomegaly, persistent growth restriction, unexplained macrosomia, or characteristic congenital anomalies should prompt consideration of molecular causes.

Environmental influences may also modify imprinting marks. Maternal diabetes, nutritional imbalance, inflammation, hypoxia, medications, and altered placental perfusion have been associated in research settings with changes in epigenetic regulation, but causality is not established for most individual exposures. Clinical counseling should distinguish proven genetic mechanisms from observational associations and should avoid attributing an imprinting disorder to maternal behavior without supporting evidence.

Clinical Features

Clinical presentation varies according to the affected locus, timing of the molecular event, and degree of mosaicism. Fetal growth restriction may occur with reduced abdominal circumference, abnormal Doppler findings, oligohydramnios, or impaired placental function. Overgrowth may present as increased fetal size, macroglossia, abdominal wall abnormalities, organomegaly, or neonatal hypoglycemia. Some fetuses have relatively normal growth but develop congenital anomalies, placental enlargement, or an unusual pattern of body asymmetry.

After birth, relevant findings can include poor feeding, hypoglycemia, hypotonia, developmental delay, obesity, short stature, asymmetric growth, endocrine dysfunction, and renal abnormalities. Certain imprinting syndromes carry an increased risk of embryonal tumors, while others are associated with neurodevelopmental or metabolic disease. The phenotype may evolve with age, so a normal neonatal examination does not exclude clinically important epigenetic dysregulation.

Diagnosis

Diagnostic evaluation begins with detailed fetal imaging, serial growth assessment, placental evaluation, maternal and paternal medical histories, and review of prior reproductive outcomes. Standard chromosomal microarray can identify deletions, duplications, and regions of copy-neutral imbalance, but it may not detect isolated methylation abnormalities. Methylation-specific multiplex ligation-dependent probe amplification, methylation-sensitive PCR, and targeted bisulfite sequencing are commonly used to assess imprinting control regions. These methods should be selected according to the suspected syndrome and validated for the relevant tissue.

Allele-specific expression analysis requires informative heterozygous markers that distinguish parental transcripts. RNA sequencing, digital PCR, and quantitative reverse-transcription PCR can then estimate the relative contribution of each allele. Phased genome sequencing helps link variants to maternal or paternal origin, while long-read sequencing may resolve complex structural variants and methylation patterns. Testing of blood, buccal cells, chorionic villi, amniotic fluid, or placental tissue may be considered, recognizing that tissue-specific mosaicism can produce discordant results. Genetic counseling is essential before and after testing, particularly when results have implications for recurrence risk, pregnancy decisions, or tumor surveillance.

Treatment & Management

There is no single treatment that corrects all imprinting abnormalities. Management is phenotype-directed and should involve maternal-fetal medicine, clinical genetics, neonatology, endocrinology, nutrition, developmental pediatrics, and relevant surgical or oncology specialists. During pregnancy, care may include serial ultrasound, umbilical and middle cerebral artery Doppler studies, assessment of placental function, and individualized planning for delivery. The timing of delivery should balance fetal risks from continued intrauterine exposure against complications of prematurity.

Neonatal management may require glucose monitoring, feeding support, respiratory assessment, and evaluation for structural anomalies. Children with persistent growth, endocrine, renal, developmental, or metabolic abnormalities need longitudinal follow-up. Where a syndrome is associated with tumor risk, surveillance should follow specialist protocols based on the molecular diagnosis and current consensus recommendations. Families should receive clear information about uncertain findings, recurrence risk, reproductive options, and the limitations of prenatal prediction.

Recent Advances / Emerging Therapies

Recent research has expanded from locus-specific methylation testing toward integrated analysis of genome sequence, epigenome, transcriptome, and chromatin architecture. Single-cell sequencing may reveal cell-lineage-specific imprinting defects in placenta and fetal tissues that are obscured in bulk samples. Improved phasing methods allow investigators to determine whether an expression imbalance is linked to a parental variant, an epigenetic alteration, or a structural rearrangement. Computational tools are also being developed to distinguish pathogenic allelic imbalance from normal developmental variability.

Experimental therapies remain investigational. Laboratory studies are exploring targeted epigenome editing, restoration of allele-specific transcription, correction of pathogenic regulatory variants, and stem-cell models that reproduce imprinting disorders. These approaches face substantial barriers, including the need for precise tissue targeting, avoidance of unintended epigenetic changes, and long-term assessment of effects across development. At present, supportive care, surveillance, and prevention of complications remain the clinical standard.

Guideline Recommendations

Professional guidance generally supports referral to clinical genetics when fetal growth abnormalities are severe, unexplained, recurrent, discordant with parental stature, or accompanied by structural findings or placental abnormalities. Molecular testing should be guided by phenotype and performed in accredited laboratories using validated assays. A negative result from one tissue or one platform should not automatically exclude an imprinting disorder when clinical suspicion remains high. Multidisciplinary review is recommended for uncertain or mosaic findings.

Clinicians should document the suspected mechanism, the tissue tested, assay limitations, and the interpretation of variants according to recognized standards for genomic and epigenomic classification. Counseling should address the distinction between an epigenetic mark and a DNA sequence variant, because recurrence risk differs substantially between sporadic methylation defects, inherited imprinting-center changes, and chromosomal abnormalities. Pregnancy management should remain individualized and should incorporate established obstetric principles for fetal growth restriction or overgrowth rather than relying on molecular findings alone.

Conclusion

Allelic imbalance analysis provides a mechanistic framework for understanding how parent-of-origin effects influence fetal growth, placental function, and lifelong disease risk. Its greatest clinical value lies in explaining otherwise unresolved patterns of fetal growth abnormality, identifying syndromic disease, refining recurrence counseling, and directing postnatal surveillance. Accurate interpretation requires integration of methylation status, allele-specific expression, genomic phasing, tissue context, phenotype, and family history. As sequencing and single-cell epigenomic technologies improve, diagnosis will become more sensitive and biologically informative. Until targeted epigenetic therapies are proven safe and effective, coordinated surveillance and multidisciplinary supportive care remain the principal means of reducing complications.